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Because EETs, particularly 11,12-EET, and the HO system share overlapping biological activities, we examined a possible link between 11,12-EET and HO activity in the regulation of vascular tone in rat mesenteric microvessels. We report here that 11,12-EET dilated rat mesenteric arteries via an HOdependent mechanism, acting through K Ca channels. The 5,6-EET, 8,9-EET, and 14,15-EET vasodilated mesenteric arteries. However, only 8,9-EET acted through a mechanism similar to that of 11,12-EET, whereas the 5,6-EET vasodilator effect was independent of HO and guanylyl cyclase and the effect of 14,15-EET was only partly reduced by chromium mesoporphyrin (CrMP).
MATERIALS AND METHODS

Chemicals.
CrMP was obtained from Porphyrin Products (Logan, UT), and 5,6-, 8,9-, 11,12, and 14,15-EET were from Cayman Chemical (Ann Arbor, MI). All other chemicals were obtained from Sigma (St. Louis, MO). ACh was dissolved in deionized water and diluted with Krebs buffer. CrMP was dissolved in a solution of 50 mM NaCO 3. Indomethacin was dissolved in ethanol and diluted with Krebs buffer. CORM-3 was a generous gift from Dr. J. R. Falck and was dissolved in water and then in Krebs buffer.
Mesenteric microvessels. The study was performed on adult male Wistar rats (Charles River, Calco, Italy), with body weights of 200 -225 g. The third-and fourth-order branches of the superior mesenteric artery (Ͻ350 m in diameter, 1-2 mm in length) were removed from the mesenteric vascular bed (4, 21) and mounted on glass micropipettes in a water-jacketed perfusion chamber (Living Systems Instrumentation, Burlington, VT) in warmed (37°C), oxygenated (95% O 2-5% CO2) Krebs-Henseleit buffer solution. The vessels were mounted on a micropipette connected to a pressure servo controller. Subsequently, the lumen of the vessel was flushed to remove residual blood, and the end of the vessel was mounted on a micropipette connected to a three-way stopcock. The vessel was pressurized to 80 mmHg and superfused with Krebs-Henseleit buffer solution (4 ml/min) at 37°C and gassed with 95% O 2-5% CO2. Vascular diameters were measured by a video system, which included a microscope with a CCD television camera (Eclipse TS100-F, Nikon, Tokyo, Japan), a television monitor (Ultrak, Lewisville, TX), and a video measuring system (Living Systems Instrumentation). After 45 min of equilibration, the presence of a functional endothelium was confirmed by relaxation to ACh (10 Ϫ6 M) after preconstriction with 18 O) were injected into samples, and the CO content of the headspace gas (expressed as pmol ⅐ mg protein Ϫ1 ⅐ 60 min Ϫ1 ) was determined by gas chromatography/mass spectroscopy analysis as previously reported (1).
Statistical analyses. The data are presented as the means Ϯ SE. Statistical significance (P Ͻ 0.05) among experimental groups was determined by the Fisher method of analysis of multiple comparisons. For comparison among treatment groups, the Null hypothesis was tested by a single-factor ANOVA for multiple groups or unpaired t-test for two groups.
RESULTS
Differential effects of CrMP, ODQ, and iberiotoxin on 11,12-EET-induced vasodilatation.
The 11,12-EET caused a dose-dependent increase in diameter (Fig. 1A) of mesenteric arterial segments preconstricted with PE. Indomethacin did not affect the vascular response to 11,12-EET (data not shown). Inhibition of HO with CrMP abolished the vasodilation produced by 11,12-EET (Fig. 1A) , suggesting that activation of HO contributes to the mechanism of the vascular action of 11,12-EET. In contrast, the response to ACh was not affected by inhibition of HO with CrMP (Fig. 1B) . To address a possible interaction with cGMP, we evaluated the mesenteric arterial response to inhibition of soluble guanylyl cyclase with ODQ. ODQ reduced the vasodilator response to ACh by ϳ50% (Fig. 1D ) but did not affect the response to 11,12-EET (Fig. 1C) . To evaluate whether the mesenteric vasodilator action of 11,12-EET was dependent on activation of K Ca channels, we determined the ability of the K Ca channel inhibitor, iberiotoxin, to affect the vascular response to 11,12-EET. Iberiotoxin (25 nM) abolished the vasodilatation produced by 11,12-EET (Fig. 1E) .
Effect of different EETs on mesenteric microvessel tone. We then evaluated the effects of the other EETs on mesenteric microvessels. The 5,6-, 8,9-, and 14 -15-EETs caused a dose-dependent increase in diameter of variable magnitude (Fig. 2) of the mesenteric arterial segments preconstricted with PE. CrMP abolished the effect of 8,9-EET (Fig. 2B) and partially inhibited the effect of 14,15-EET (Fig. 2C) , but it did not affect vasodilatation to 5,6-EET (Fig. 2A) . Furthermore, ODQ did not affect vasodilatation to 5,6-EET ( Fig. 2A) and 8,9-EET (Fig. 2B) , whereas it decreased the effect of 14,15-EET (Fig. 2C) .
Effect of 11,12-EET on HO activity. To confirm that the effect of 11,12-EET on mesenteric microvessels was mediated by activation of HO, we incubated the microvessels with 11,12-EET and measured CO release. As shown in Fig. 3 , 11,12-EET caused a 30% increase in CO release from mesenteric microvessels. To ascertain whether 11,12-EET mediated the increase in HO activity, mesenteric microvessels were treated with 11,12-EET and CrMP. The addition of CrMP prevented the 11,12-EET-mediated increase in HO activity.
Effect of CORM-3 on mesenteric microvessel tone. To ascertain whether mesenteric microvessels respond to exogenous CO, a CO-donor (CORM-3) was applied to vessels preconstricted with PE. When added to a buffer with normal pH, CORM-3 releases CO. The CO released by CORM-3 caused vasodilatation of mesenteric microvessels only when pretreated with CrMP (Fig. 4) .
DISCUSSION
Because 11,12-EET shares many of the effects that derive from activation of HO, the possibility that some actions of 11,12-EET are mediated by an HO-dependent mechanism has been examined in the present study and has been answered in the positive for rat mesenteric arterial vessels. Indeed, our results suggest that a key mechanism of action of 11,12-EET on rat mesenteric arteries is driven by stimulation of HO activity. This novel observation was substantiated by enzymatic activity, indicating that 11,12-EET increased HO activity as measured by increased CO production that was abolished by inhibition of HO with CrMP (Fig. 3) . That a product of HO activity mediates the vasodilator action of 11,12-EET in the mesenteric microcirculation is supported by our results showing that vasodilation to 11,12-EET was independent of COX and was unaffected by inhibition of cGMP formation but was abolished by inhibition of HO with CrMP and of K Ca channels with iberiotoxin. These findings are in agreement with those of Naik et al. (18) who demonstrated that CO, a product of HO, dilated the mesenteric circulation. Previous findings that depolarization of vascular smooth muscle (VSM) cells with a high-K ϩ media and blockade of K Ca channels with iberiotoxin, charybdotoxin, or tetraethylammonium prevented the vasodilator response to EETs provide strong support for a primary role of K ϩ channels in mediating the vasodilator response to EETs (5, 8) . Several investigators found that EETs have no effect on the activity of the K Ca channel in inside-out detached membrane patches excised from VSM cells (26) , suggesting that EETs do not directly activate the K Ca channel in VSM.
CO directly activates K Ca channels in vascular smooth muscle cells by altering the apparent calcium dependence of K Ca channel activation (10, 13, 18, 26) . The mechanisms of action of endogenous vs. exogenous CO are different. Naik et al. (18) showed that the effect of exogenous CO is sensitive to ODQ and iberiotoxin, whereas the effect of endogenous CO is cGMP independent, via activation of large-conductance K Ca channels. Thus the effects of 11,12-EET and CO share similarities; our study suggests that the most important mechanism of action of 11,12-EET on the mesenteric microcirculation is through stimulation of endogenous CO production acting on K Ca channels. Because vasodilatation to 11,12-EET was not inhibited by ODQ, whereas the effect of ACh was partially inhibited by ODQ, we can also exclude an effect of 11,12-EET through nitric oxide.
In response to 11,12-EET, the rabbit renal vasculature dilated independently of cyclooxygenase (6), as did the rat renal arcuate, interlobular, and afferent arterioles (7). 5,6-EET also dilated the rat renal arcuate artery (7) and the rabbit renal vasculature (6); however, in contrast to 11,12-EET, it exhibited a cyclooxygenase dependency. In our mesenteric microvessels, 5,6-EET caused vasodilatation that could not be blocked by inhibition of HO with CrMP. Additionally, the dilator response of the renal afferent arteriole to the sulfonimide analog of 11,12-EET was unaffected by guanylyl cyclase inhibition (11), as was the case for dilation of superior mesenteric arterial vessels in the present study (Fig. 1C) . The vascular responses to both 11,12-EET and CO were inhibited by blockade of K Ca channels (20, 26) . Dependency of the vascular action on HO activity was evident for 8,9-EET (Fig. 2B ) and accounted partially for the mesenteric vasodilator effect of 14,15-EET (Fig. 2C) but not for 5,6-EET ( Fig. 2A) . Thus the mechanism of the vascular action for each EET demonstrated a degree of specificity. However, species differences, experimental conditions (in vivo vs. in vitro), vascular territories (coronary vs. renal), and different blood vessel sizes (conduit arteries vs. arterioles) are factors that urge caution when interpreting differences noted on comparing studies of vascular responses to eicosanoids.
In conclusion, our results suggest a close interaction involving 11,12-EET and the HO/CO system in rat mesenteric arteries; namely, rat mesenteric vasodilation produced by 11,12-EET is related to activation of the HO system.
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